/
Dermatology
Prurigo Nodularis
11
Pipeline Programs↗
16
Active Trials↗
17
Companies Involved↗
Prurigo Nodularis is an emerging landscape with 11 programs across 17 companies. The most active players are Incyte, Guangdong Hengrui Pharmaceutical Co., Ltd, Celldex Therapeutics. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 35
Approved
No programs
Analysis
Modality Breakdown
60%
Small molecule
6 of 10 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
37
clinical trials
Completed17 · 46%
Recruiting9 · 24%
Active, not recruiting6 · 16%
Unknown status3 · 8%
Not yet recruiting1 · 3%
Terminated1 · 3%
Clinical Trials
Trial Activity
37 trials
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)